Docosahexaenoic Acid Serving as Sensitizing Agents and Gefitinib Resistance Revertants in EGFR Targeting Treatment

OncoTargets and Therapy - New Zealand
doi 10.2147/ott.s225918
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Omega-3 Long Chain Polyunsaturated Fatty Acids as Sensitizing Agents and Multidrug Resistance Revertants in Cancer Therapy

2017English

Docosahexaenoic Acid Monoglyceride Increases Carboplatin Activity in Lung Cancer Models by Targeting EGFR

Anticancer Research
MedicineCancer ResearchOncology
2017English

Epigenetic Silencing of miR-483-3p Promotes Acquired Gefitinib Resistance and EMT in EGFR-mutant NSCLC by Targeting Integrin Β3

Oncogene
Cancer ResearchGeneticsMolecular Biology
2018English

Author Correction: Targeting Hsp90 With FS-108 Circumvents Gefitinib Resistance in EGFR Mutant Non-Small Cell Lung Cancer Cells

Acta Pharmacologica Sinica
MedicinePharmacology
2020English

Brief Report: Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced Non–Small-Cell Lung Cancer With Sensitizing EGFR Mutation

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Allosterically Targeting EGFR Drug-Resistance Gatekeeper Mutations

Journal of Thoracic Disease
PulmonaryRespiratory Medicine
2017English

Linc01014 Regulates Gefitinib Resistance in Oesophagus Cancer via EGFR‐PI3K‐AKT‐mTOR Signalling Pathway

Journal of Cellular and Molecular Medicine
Molecular MedicineCell Biology
2019English

Insulin Sensitizing Agents and Polycystic Ovary Syndrome

European Journal of Endocrinology
MedicineEndocrinologyMetabolismDiabetes
1998English

Targeting Autophagy for Overcoming Resistance to Anti-Egfr Treatments

Cancers
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy